2022
Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer
Adua S, Arnal-Estapé A, Zhao M, Qi B, Liu Z, Kravitz C, Hulme H, Strittmatter N, López-Giráldez F, Chande S, Albert A, Melnick M, Hu B, Politi K, Chiang V, Colclough N, Goodwin R, Cross D, Smith P, Nguyen D. Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer. Nature Communications 2022, 13: 7690. PMID: 36509758, PMCID: PMC9744876, DOI: 10.1038/s41467-022-34889-z.Peer-Reviewed Original ResearchConceptsGene expression programsRas homolog family member ACancer cellsFamily member AEpidermal growth factor receptorExpression programsMetastatic cancer cellsSRF signalingGrowth factor receptorTumor microenvironmentLung cancerFunctional linkExtracellular lamininDrug-resistant cancer cellsMutant non-small cell lung cancerNon-small cell lung cancerCentral nervous system relapseMolecular studiesMember AEGFR-mutant lung cancerFactor receptorNervous system relapseCell lung cancerDisseminated tumor cellsBrain tumor microenvironment
2018
Pre-Conditioning the Airways of Mice with Bleomycin Increases the Efficiency of Orthotopic Lung Cancer Cell Engraftment.
Stevens LE, Arnal-Estapé A, Nguyen DX. Pre-Conditioning the Airways of Mice with Bleomycin Increases the Efficiency of Orthotopic Lung Cancer Cell Engraftment. Journal Of Visualized Experiments 2018 PMID: 30010648, PMCID: PMC6102009, DOI: 10.3791/56650.Peer-Reviewed Original ResearchConceptsCancer cell engraftmentAirways of miceLung cancer cellsCell engraftmentLung cancerTumor cellsTumorigenic capacityNew orthotopic modelNon-physiological sitesTumor cell injectionCancer cellsLung tumor incidenceTreatment-refractory diseaseFull clinical spectrumLung cancer subtypesLung adenocarcinoma subtypesAdditional animal modelsStrains of miceFlanks of miceRefractory diseaseThoracic malignanciesAdenocarcinoma subtypeClinical spectrumOrthotopic transplantationTumor incidence